Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern

Immunology and Cell Biology

Volumn 82, Issue 6, 2004, Pages 603-610

  Pérez, Oliver ^a   Bracho, Gustavo ^a   Lastre, Miriam ^a   Mora, Nestor ^a   Del Campo, Judith ^a   Gil, Danay ^a   Zayas, Caridad ^a   Acevedo, Reinaldo ^a   González, Domingo ^a   López, José A ^b   Taboada, Carlos ^a   Solis, Rosa L ^a  

^a FINLAY INSTITUTE   (Cuba)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Adjuvant; Cochleate structure; Immunization; Th1 response; Vaccine

Indexed keywords

ANTIBODY; ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MENINGOCOCCUS VACCINE; NITRIC OXIDE; OUTER MEMBRANE PROTEIN; OVALBUMIN; OVALBUMIN ANTIBODY; PARASITE ANTIGEN; PHOSPHOLIPID; PROTEOLIPOSOME ANTIBODY; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSTIMULATION; LEISHMANIA MAJOR; LEISHMANIASIS; MOLECULAR STABILITY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PARENTERAL DRUG ADMINISTRATION; PROTEOLIPOSOME; PROTEOLIPOSOME DERIVED COCHLEATE STRUCTURE; SALIVA; SPLEEN CELL; TH1 CELL; TH2 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; HYPERSENSITIVITY, DELAYED; LEISHMANIA MAJOR; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS; PROTEOLIPIDS; TH1 CELLS;

ANIMALIA; LEISHMANIA MAJOR; MENINGOCOCCUS; NEISSERIA MENINGITIDIS; PROTOZOA;

EID: 9444236224     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2004.01293.x     Document Type: Article

References (20)

1. Palucka K, Banchereau J. How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr. Opin. Immunol. 2002; 14: 420-31.
2. Van Eden W, van der Zee R, van Kooten P et al. Balancing the immune system: Th1 and Th2. Ann. Rheum. Dis 2002; 61: 25-8.
3. Pérez O, Bracho G, Lastre M et al. Método de obtención de estructuras cocleares. Composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios. 2002. Patent application Cu 2002-0292.
4. O'Hagan D, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nature Rev. 2003; 2: 727-35.
5. Harandi AM, Sanchez J, Eriksson K, Holmgren J. Recent developments in mucosal immunomodulatory adjuvants. Current Opinion Invest Drugs 2003; 4: 156-61.
6. Reis e Sousa C. Dendritic cells as sensors of infection. Immunity 2001; 14: 495-8.
7. Kaisho T, Akira S. Toll-like receptors as adjuvants receptors. Biochim. Biophys. Acta 2002; 1589: 1-13.
8. Sierra VG, Campa C, Varcácel M. Vaccine against group B Neisseria meningitides: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991: 195-207.
9. Perez O, Lastre M, Lapinet J et al. Immune response induction and new effectors mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine. Infect. Immun. 2001; 69: 4502-508.
10. Kolb-Maurer A et al. Interaction of Neisseria meningitidis with human dendritic cells. Infect. Immun. 2001; 69: 6912-22.
11. Papahadjopoulos D, Vail WJ, Jacobson K et al. Cochleate lipid cylinders: Formation of unilamellar lipid vesicles. Biochim. Biophys. Acta 1975; 394: 438-91.
12. Campa C, Sierra VG, Gutiérrez MM et al. Method of producing Neisseria meningitidis B vaccine, and vaccine produced by method. United States Patent 1997. Patent number 5 597 572.
13. Chatelain R, Mauze S, Coffman RL. Experimental Leishmania major infection in mice: role of IL-10. Parasite Immunol. 1999; 21: 974-9.
14. Rockett KA, Awburn MM, Aggarwal BB, Cowden WB, Clark IA. In vivo induction of nitrite and nitrate by tumor necrosis factor, lymphotoxin, and interleukin-1: possible roles in malaria. Infect. Immun. 1992; 60: 3725-30.
15. Kalinski P, Hilkens C, Wierenga EA, Kpsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immnol. Today 1999; 20: 561-7.
16. Murtaugh MP, Foss DL. Inflammatory cytokines and antigen presenting cell activation. Vet. Immunol. Immunopathol. 2002; 87: 109-21.
17. Niedbala W, Wei XQ, Liew FY et al. Effects of nitric oxide on the induction and differentiation of Th1 cells. Eur. J. Immunol. 1999; 29: 2498-505.
18. Brandtzaeg P. Role of secretory antibodies in the defense against infections. Int. J. Med. Microbiol. 2003; 293: 3-15.
19. Fujihashi K, Kato H, van Ginkel FW et al. A revisit of mucosal IgA immunity and oral tolerance. Acta Odontol. Scand. 2001; 59: 301-308.
20. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2002; 2: 845-58.